174 related articles for article (PubMed ID: 20941459)
1. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Barrett YC; Wang J; Knabb R; Mohan P
Thromb Haemost; 2011 Jan; 105(1):181-9. PubMed ID: 20941459
[TBL] [Abstract][Full Text] [Related]
2. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
[TBL] [Abstract][Full Text] [Related]
3. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
; Buller H; Deitchman D; Prins M; Segers A
J Thromb Haemost; 2008 Aug; 6(8):1313-8. PubMed ID: 18541000
[TBL] [Abstract][Full Text] [Related]
5. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
6. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
7. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
8. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
11. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
12. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
[TBL] [Abstract][Full Text] [Related]
13. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
[TBL] [Abstract][Full Text] [Related]
14. Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism.
Browne C; Lanitis T; Hamilton M; Li X; Horbyluk R; Mardekian J; Kongnakorn T; Cohen A
J Med Econ; 2017 Jan; 20(1):98-106. PubMed ID: 27822962
[TBL] [Abstract][Full Text] [Related]
15. Blood coagulation and thrombosis in patients with ovarian malignancy.
von Tempelhoff GF; Dietrich M; Niemann F; Schneider D; Hommel G; Heilmann L
Thromb Haemost; 1997 Mar; 77(3):456-61. PubMed ID: 9065993
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
17. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
18. Treatment of deep venous thrombosis with low molecular weight heparin in pediatric cancer patients: safety and efficacy.
Tousovska K; Zapletal O; Skotakova J; Bukac J; Sterba J
Blood Coagul Fibrinolysis; 2009 Oct; 20(7):583-9. PubMed ID: 19620843
[TBL] [Abstract][Full Text] [Related]
19. Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation.
Siragusa S; Anastasio R; Giarratano A; Malato A; Bonifacio G; Arcara C; Gebbia N
Exp Oncol; 2004 Sep; 26(3):192-5. PubMed ID: 15494686
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
